0
Experience
Adverse event associated with a change in nonprescription syringe sale policy
Nickolas D. Zaller, PhD; Michael A. Yokell; Alexandra Jeronimo, MPH; Jeffrey P. Bratberg, PharmD, BPharm, BCPS; Patricia Case, ScD, MPH; Josiah D. Rich, MD, MPH
J Am Pharm Assoc (2003) 2010;50:619-622. doi:10.1331/JAPhA.2010.09162

Abstract

Objective  To report and describe the possible correlation of a change in syringe sale policy at a community pharmacy with an adverse clinical outcome.

Setting  Providence, RI, in summer 2009.

Patient description  27-year-old white woman with a long-standing history of chronic relapsing opiate addiction and human immunodeficiency virus (HIV)/hepatitis C virus (HCV) coinfection.

Case summary  The patient presented to the hospital emergency department with 5 days of severe diffuse pain, swelling in her hands and feet, and several days of rigors with fevers, sweats, and chills. She was diagnosed with sepsis resulting from a disseminated methicillin-resistant Staphylococcus aureus (MRSA) infection. The patient was treated with intravenous antibiotics, neurosurgical drainage of an epidural abscess, intensive care unit care for 1 week, and acute hospitalization for 8 weeks.

Main outcome measures  Not applicable.

Results  A few weeks before the patient was hospitalized, pharmacists at her local neighborhood pharmacy decided to stop selling syringes in packages of 10. Instead, syringes were sold at a minimum quantity of 100. The patient did not know where to obtain sterile syringes and began reusing syringes.

Conclusion  The patient introduced pathogenic bacteria from her skin into her bloodstream through unsafe injection practices. The change in syringe sale policy at her local pharmacy likely inadvertently contributed to this severe and life-threatening situation. Consideration of the implications of syringe sale policy must include an understanding of the barriers that influence individual pharmacist's decisions regarding particular store policies that affect over-the-counter syringe sales. Legalized sale of nonprescription syringes in community pharmacies alone is not enough to curb the epidemic of unsafe injection practices in the United States. All medical risks that are inherent in the use of unsafe syringes, including blood-borne viral pathogens (e.g., HIV, HCV) and bacterial infections (e.g., MRSA), should be considered.

Sign In
APhA Members 
Welcome to JAPhA.org! Please log in below using your APhA username and password. Update your APhA profile.
Not a Subscriber
New to JAPhA? Become an APhA member to receive a full subscription to both the print and online editions.

OR

Register for a FREE limited account to benefit from personalization features such as alerts.

References

Broadhead RS, Hulst  van Y, Heckathorn DD.  The impact of a needle exchange's closure.  Public Health Rep. 1999;114:439–47.[PubMed][CrossRef]
 
Normand J, Vlahov D, Moses LE.  Preventing HIV transmission: the role of sterile needles and bleach. Washington, DC:  National Academies Press;  1995.
 
Rich J, Strong L, Mehrotra M, Macalino G. Strategies to optimize the impact of needle exchange programs.  AIDS Read. 2000;10:421–9.[PubMed]
 
Battles HB, Rowe KA, Ortega-Peluso C, et al. Who purchases nonprescription syringes? Characterizing customers of the Expanded Syringe Access Program (ESAP).  J Urban Health. 2009;86:946–50.[PubMed]
 
Holtgrave DR, Pinkerton SD, Jones TS, et al. Cost and cost-effectiveness of increasing access to sterile syringes and needles as an HIV prevention intervention in the United States.  J Acquir Immune Defic Syndr Hum Retrovirol. 1998;18(suppl 1):S133–8.[PubMed]
 
Laufer FN.  Cost-effectiveness of syringe exchange as an HIV prevention strategy.  J Acquir Immune Defic Syndr. 2001;28:273–8.[PubMed]
 
Des Jarlais DC, Perlis T, Arasteh K, et al. HIV incidence among injection drug users in New York City, 1990 to 2002: use of serologic test algorithm to assess expansion of HIV prevention services.  Am J Public Health. 2005;95:1439–44.[PubMed]
 
Watters JK, Estilo MJ, Clark GL, Lorvick J. Syringe and needle exchange as HIV/AIDS prevention for injection drug users.  JAMA. 1994;271:115–20.[PubMed]
 
 Rhode Island Department of Health. Rules and regulations governing hypodermic needles, syringes and other such instruments. R21-28-CS-4. Providence, RI:  Rhode Island Department of Health;  2002:4.
 
Singer M, Baer HA, Scott G, et al. Pharmacy access to syringes among injecting drug users: follow-up findings from Hartford, Connecticut.  Public Health Rep. 1998;113(suppl 1):81–9.[PubMed]
 
Tesoriero JM, Battles HB, Klein SJ, et al. Expanding access to sterile syringes through pharmacies: assessment of New York's Expanded Syringe Access Program.  J Am Pharm Assoc. 2009;49:407–16.
 
Rich J, Martin E, Macalino G, et al. Pharmacist support for selling syringes without a prescription to injection drug users in Rhode Island.  J Am Pharm Assoc. 2002;42(6 suppl 2):S58–61.
 
Lewis BA, Koester SK, Bush TW.  Pharmacists’ attitudes and concerns regarding syringe sales to injection drug users in Denver, Colorado.  J Am Pharm Assoc. 2002;42(6 suppl 2):S46–51.
 
Blumenthal WJ, Springer KW, Jones TS, Sterk CE.  Pharmacy student knowledge, attitudes, and beliefs about selling syringes to injection drug users.  J Am Pharm Assoc. 2002;42(6 suppl 2):S34–9.
 
Des Jarlais DC, McKnight C, Goldblatt C, Purchase D. Doing harm reduction better: syringe exchange in the United States.  Addiction. 2009;104:1441–6.[PubMed]
 
Dwyer R, Topp L, Maher L, et al. Prevalences and correlates of non-viral injecting-related injuries and diseases in a convenience sample of Australian injecting drug users.  Drug Alcohol Depend. 2009;100:9–16.[PubMed]
 
Saravolatz LD, Markowitz N, Arking L, et al. Methicillin-resistant Staphylococcus aureus: epidemiologic observations during a community-acquired outbreak.  Ann Intern Med. 1982;96:11–6.[PubMed]
 
NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).
Please read the other comments before you post yours. Comments are moderated and will appear on the site at the discertion of the editorial staff.
* = Required Field
(if multiple authors, separate names by comma)
Example: John Doe



Related Content

Customize your page view by dragging & repositioning the boxes below.

JAPhA Articles
Topic Collections
Advertisement
 
  • Print
  • PDF Download
  • Email
  • Share
  • Get Citation
  • Submit Comment
  • Article Alerts
    Please Wait... Processing your request... Please Wait.
    You must sign in to sign-up for alerts.

    Please confirm that your email address is correct, so you can successfully receive this alert.

  • Letters To Editor
  • Reprints